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In an attempt o determine the regions responsible for type 1 immdiate hypcrsensilivily, a tolal of42 peptidc frawcnts, which cover the CH3_CW4 
domains in human immunoglobulin E (I~EJ, were clicmically synkzkcd. Several peptide fragments located in the amino acid sequences A@:9- 
Thrs5’ and Arg”9-Ala”3, inhibited passive cutaneous anaphylaxis (PCA) in viva. In order 10 pinpoint the sites responsible for the inhibition of 
the PCA reaction, various fragment pcplidL% in these Lwo regions were synthcsizcd. As a result, residues Pro”‘-LeuUn, Pr~~~-Tbr’~‘, and 
Ser’56-‘fhf10’ were suggesled 10 be involved in type I immediate hypersensitivity. 
Immunoglobulin E; Immunoglobulin E peptide fragmellt; i’assive cuianeous anaphylaxis; immediate hypersnsitivity; FCE raptor. 
1. INTRODUCTION capacity to inhibit the passive cutaneous anaphylaxis 
(PCA) reaction in vivo. 
Immunoglobulin E (IgE) is a glycoprotein of motec- 
ular weight of approximately 190 kDa which binds re- 
versibly and with high afinity to the specific membrane- 
bound Fee receptor on mast cells and basophils [I]. 
Bridging of the receptor-bound IgE by a specific antigen 
triggers the secretion of chemical mediators uch as his- 
tamine, slow-reacting substance of anaphylaxis, and 
platelet activating factor, which are responsible for type 
I immediate hypersensitivity [2,3]. By binding to and 
blocking the FCE receptor, peptide containing the 
binding site(s) will inhibit the release of the chemical 
mediators. To identify such an IgE receptor-binding 
peptide would lead to the development of an anti- 
allergic agent for immediate hypersensitivity such as 
asthma, hay fever and food allergy [4]. 
2. MATERIALS AND METHODS 
All pcptidcs used were synthesized by &c stepwise solid-phase 
method using Fmoc chemistry [IO,1 l] as described prc~iously [12,13]. 
The purity of each pepdde was confirmed by thin-layer chromatoga- 
phy, high-performance liquid chromalography, fan atom bombard- 
ment mass spectrometry. sequencing with a gus-phase microse- 
qucncer, and amino acid analysis after hydrolyzing in constant-boiling 
WCI at 110°C for 24 h. The sequences of compounds are ahown in 
Table I. 
2.2. PCA br rurs 
It has been suggested by studies with proteolytic pep- 
tide fragments of human IgE [S] and its recombinant 
gene products [6-S], as well as conformational studies 
[9], that the binding sites in the human IgE molecule are 
located in the CH3 and/or CH4 domains. The exact 
binding sites, however, remain unidentified. 
In an attempt o precisely locate the binding sites, we 
chemically synthesized a number of peptide fragments 
which cover the CH3-CH4 domains and tested their 
The capacity oflhe synlhcsized peplides to inhibit degranulation of 
masl cells in rats in vivo was measured by the PCA test. Diluted mouse 
an&es albumin antiserum [14] (100 ~1) was injected imndermally 
(i.d.) inlo the back skins of 5 male Wistar rats. After 48 h, I ml of a 
0.5% Evans’ blue solution conlaining 2 mgof egg albumin was injected 
intravenously (i.v.). The PCA reaclion was determined as a blueing 
arcr of lhe skin 30 min after the antigen challenge. To dcterminc the 
inhibition of the degranulation by the synthciicpepddcs, 3 consecutive 
i.d. injections of each peptide solution (loO@) were cnrried out inlo 
lhe same she of the back skin of the rat; 3 and 24. h before the passive 
sensitization with the andserum. and at the same lime with the anti- 
serum injection. The anti-PCA activity of fragmem peptides was ex- 
pressed as percent inhibition of the blucing area compared with the 
vehicle control, inlo which a physiological saline solution was injected 
three limes. Studenl’s r-lest was used for Lhc statisrical analysis. 
Correspondence address: N. Nio, Ccntrul Research Laboratories, 
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3. RESULTS 
Abbreviarims: These follow the recommendations oflhe IUPAC-iUB 
Joint Commission on Biochemical Nomenclature 1(19&I) Eur. J. Bio- 
them. 138, 9-391. 
A three-dimensional IgE structure could not be used 
for designing active peptides, since it has not yet been 
determined by X-ray crystallography. Therefore, we 
began with peptides which possibly bind to the FCE 
receptor, and finally covered the CH3-CH4 domains 
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Table I 
Effect of the synthetic human 1g.E peptidc fragments on heterologous 
passive cutaneous anaphylaxis (WA) in rnts 
Pcptide no. Compoundb Inhibition 
(8) 
I (329-348) 
2 (345-356) 
3 (34%3G8) 
4 (368-387) 
5 (380-399) 
6 (397-416) 
7 (417-437) 
8 (42G-440) 
9 (438-45G) 
10 (454--166) 
11 (456-470) 
12 (4G5--183) 
I3 (479-496) 
14 (485-504) 
15 (497-5 15) 
1G (514-530) 
I7 (53 l-547) 
IS (329-357) 
19 (41%163) 
20 (32 l-332) 
2 1 (329-338) 
22 (330-334) 
23 (333-344) 
24 (339-348) 
25 (343-348) 
26 (41 l-425) 
27 (419433) 
28 (426-433) 
29 (42cd34) 
30 (432-438) 
31 (434-448) 
32 (441-455) 
33 (c)49-%3) 
34 (452-461) 
35 (453-461) 
36 (454-461) 
37 (455-461) 
38 (456-4G3) 
39 (456dGl) 
40 (456-460) 
41 (457-461) 
42 (458461) 
ADSNPRGVSAYLSRPSPFDL 
PFDLFIRKSPTI 
FIRKSPTITSLWDLAPSKGd 
GTVNLTWSRASGKPV'NHSTR 
KPVNHSTRKEEKQRNGTLTV 
LTVTSTLPVGTRDWIEGETY 
QSRVTHPHLPRALMRSTTKTSd 
PRALMRSTTKTSGPR 
GPRAAPEVYAFATPEWPGS 
PGSRDKRTLASLId 
SRDKRTLASLIQNFM 
LIQNFLPEDISVQWLHNEV 
LENEVQLPDARHSTTQPR 
LPDARHSTTQPRKTKGSGFF 
KTKGSGFFVFSRLEVTRAE 
AEWEQXDEFISRAVHEA 
ASPSQTVQRAVSVNPGKd 
ADSNPRGVSAYLSRPSPFDLFIRKSPTIT 
RVTHPHLPRALMRSTTKTSGPRAAPEVYA 
FATPEWPGSRDKRTLA 
FEDSTXKSADSNd 
ADSNPRGVSA 
DSNPR 
PRGVSAYLSRPS 
YLSRPSPFDL 
PSPFDL 
IEGETYQSRVTHPHLd 
RVTHPHLPRALMRST 
PRALMRST 
PRALMRSTT 
STTKTSG 
TKTSG?RAAPEVYAF 
AAPEVYAFATPEWPG 
ATPSWPGSYDYRTLA . . 
EWPGSRDKRT 
WPGSRDKRT 
PGSRDKRT 
GSROKRT 
SRDKRTLA 
SRDKRT 
SRDKR 
RDKRT 
DKRT 
23.2* 
15.9” 
13.2 
8.2 
9.3 
-6.1 
20.0* 
33.2* 
25.4* 
25.3** 
25.2** 
I 1.6c 
-2.7 
5.3 
-4.8 
-4.8 
-2.7 
32.4* 
32.Y 
12.3 
2.4 
-12.2 
13.7 
-3.9 
17.9* 
7.0 
-6.2 
25.Y 
9.5 
-3.8 
-18.9* 
12.1 
S.0 
13.9 
1.8 
-5.8 
16.gp* 
23.0 
20.1’* 
15.1 
23.2 
9.4 
“Nmbws in parentheses indicate the position in human IgE 191. 
‘The single-letter notation for amino acids is used. 
‘Each peptidc (100 ,ug/site) was injected intradermally. 
‘Cys was replaced with Ser. 
Verccnt inhibition of PCA at 30 ,udsits i.d. 
*P =z 0.05, **P < 0.01, significnntly different from the matched vehicle 
control. 
which partially overlap each other. The possible binding 
regions in the CH3 and CH4 domains for the FW rccep- 
+A.. II,PPLI n~.-l;~+nrl by s~fi~nrl~~\~ EE..,I.+,.~P I1 61 opne fnr LY. ..I._ p.wH.w.wH rruAArrr., "..9a".ba.W L.-J," W&&Y.". 
hydrophobic [16] and hydrophilic residues [17], the 
model of the three-dimensional structure of human IgE 
constructed by Padlan and Davies [lS], and the study 
Fig. 1. The amino acid sequence of the CM3 and 014 domains oT the 
human IgE molecule, and the positions of the two regions (1 and 2) 
with inhibitory activity on the PCA reaction. 
of homologous sequences among immunoglobulins. In 
the synthesis, the cysteinc residues of the disulfide 
bridges in IgE [19], which are assumed not to be in- 
volved in the binding between IgE and its receptor, were 
replaced by serine residues. 
Table I summarizes the results of the inhibitory activ- 
ity of the synthetic peptides on PCA. Compounds 1, 2, 
7, 8, 9, 10 and 11 in a series of compounds l-l?, which 
cover the CH3-CH4 domains, significantly inhibited 
the PCA reaction (Table I). These peptides were located 
in the amino acid sequences Ala319-Thr357 (Region 1) 
atid Arb *“‘9-A1a463 (Region 2), as shown in Fig. 1. There- 
fore, compounds 18 and 19, which correspond to Re- 
gions 1 and 2, respectively, were synthesized and they 
significantly inhibited the PCA reaction (Table I). In 
addition, compounds 20-42 in these two regions were 
synthesized in crder to define the sites responsible for 
the inhibition of PCA. Compounds 25, 28, 37 and 39 
inhibited the PCA reaction. Therefore, three sites 
(Pro343-Leu348, Prod2G-Thr”33, and Ser”3G-Thr’“‘) were 
suggested to be involved in the PCA reaction. 
4. DISCUSSION 
In the present study. we synthesized a series of 42 
peptide fragments of human IgE, which cover the CH3- 
CH4 domains, and assayed them for their capacity to 
inhibit the PCA reaction in rats. The peptide fragments 
which inhibited PCA were located in the sequences 
Ala3’g-Thr357 in the .CH3 domain (Region 1) and 
Arg“19-Ala~63 in the junction between the CM3 and CM4 
domains (Region 2). This finding supported the previ- 
ous idea that the CH3 and/or CH4 domains played an 
important role in the binding of IgE to its receptor. 
Recently, Helm et al. prepared a series of overlapping 
recombinant FCE gene products and suggested that the 
IgE receptor-binding site on human IgE was located 
within a sequence of 76 amino acids at the CH21CH3 
junction (containing the Gln30’-Arg376 sequence) 1201. 
Region 1 is included in Helm’s peptide fragment. One 
of the FCE receptor binding sites would probably be 
ln.w-A+nA :q ?*& 
s 
:‘-bn 1 
.YIH.eY . . .Y.. I. 
In addition, various fragment peptides in these re- 
gions were synthesized in order to locate the sites re- 
sponsible for PCA inhibition. Residues Pro3’3-Leu34M, 
230 
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Pro’26-Thr’33, and SerJSG-Thr”6’ were identified as being 
responsible for PCA inhibition in rats. These three sites 
in human IgE were not homologous with those in 
human IgAl, IgD, IgGl and IgM, as determined by 
sequence homology analysis [21]. Since among human 
immunoglobulins only human IgE binds to its Fcs re- 
ceptor with high affinity, the amino acid sequences of 
the binding sites of IgE should not be homologous with 
those of other immunoglobulins. On the other hand, 
these three sites in both human and rodent IgE have a 
comparatively high degree of homology and the same 
type of amino acids with regard to charge or hydropho- 
bicity. In general, physiologically important amino 
acids are conserved. It has also been suggested that 
human IgE and rodent IgE share common structures in 
the Fc portion of molecules [22]. The three sites in 
human IgE were indeed relatively homologous with the 
corresponding sites in rodent IgE [6,23,24], but not with 
those in human IgAl, IgD, lgG1 and IgM [21]. In addi- 
tion, the three active sites were located on the surface 
of the stereoview model of the FCE portion of human 
IgE [18], which was constructed using a known three- 
dimensional structure of the IgG Fc site. This result 
indicates that the Fcs receptor binding site(s) is exposed 
to the surface of the IgE molecule. 
From the results, we have tentatively concluded that 
the three sites (Pro343-Leu3’8, Pro4’6-Thr’33, and Ser*“6- 
Thti6’) in the CM3 and CH4 domains are responsible 
for type I immediate hypersensitivity, and may also 
contribute to binding of the IgE molecule to its receptor. 
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